88
Participants
Start Date
July 11, 2022
Primary Completion Date
January 31, 2025
Study Completion Date
January 31, 2025
Niraparib Oral Product
Niraparib (\[3S\]-3-\[4-\[7-(aminocarbonyl)-2H-indazol-2-yl\] phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, and highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose monohydrate and magnesium stearate. Niraparib will be supplied in bottles containing 72 capsules of 100 mg. The capsules should be swallowed whole with water. The capsules should not be chewed or crushed and can be taken without regard to meals.
Active Symptom Control
ASC could involve regular specialist follow up; structured assessment of physical, psychological, and social problems; and appropriate treatment, including palliative radiotherapy and steroids.
University Hospital Southampton, Southampton General Hospital, Southampton
Medway NHS Foundation Trust, Medway Maritime Hospital, Gillingham
Somerset NHS Foundation Trust, Musgrove Park Hospital, Taunton
Belfast Health and Social Care Trust, Belfast City Hospital, Belfast
Velindre University NHS Trust, Velindre Cancer Centre, Cardiff
Beatson West of Scotland Cancer Centre, Glasgow
The Princess Alexandra Hospital NHS Trust, The Princess Alexandra Hospital, Harlow
Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Hull
Leeds Teaching Hospitals NHS Trust, St James's Hospital, Leeds
University Hospitals of Leicester NHS Trust, Royal Leicester Infirmary, Leicester
Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield
University of Southampton
OTHER
British Lung Foundation
OTHER
University Hospital Southampton NHS Foundation Trust
OTHER